Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple dose study of izencitinib in healthy Japanese and Caucasian adults
NCT03750565Phase 1Completed
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Nov 2018
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of izencitinib in inflammatory bowel disease (IBD) (4 cohorts), sponsored by Theravance Biopharma, Inc. Primary endpoints: Area under the concentration-time curve (AUC0 t) at Day 14, Area under the concentration-time curve (AUC0 24) at Day 14 and 3 more. Started Nov 2018; status: completed.
02
Drugs
izencitinib
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT03750565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03750565.